Toward a gene therapy for neurological and somatic MPSIIIA.
Open Access
- 1 January 2013
- journal article
- Published by Taylor & Francis Ltd in Rare Diseases
- Vol. 1 (1), e27209
- https://doi.org/10.4161/rdis.27209
Abstract
Mucopolysaccharidosis Type IIIA (MPSIIIA) represents an unmet medical need. MPSIIIA shares with many other lysosomal storage disorders (LSD) the characteristic of being a severe neurodegenerative disease accompanied by mild somatic involvement. Thus, the main target organ for the development of new treatments is the central nervous system (CNS), but overall clinical efficacy would be greatly enhanced by simultaneous correction of peripheral disease. We have recently developed a novel treatment for MPSIIIA based on the delivery to the cerebrospinal fluid of serotype 9 adeno-associated virus (AAV9)-derived vectors. This gene therapy strategy corrected both CNS and somatic pathology in animal models through widespread transduction of CNS, peripheral nervous system (PNS), and liver. The work set the grounds for the clinical translation of the approach to treat MPSIIIA in humans. Here we discuss some important considerations that further support the applicability of this treatment to MPSIIIA and other LSD with CNS and somatic involvement.Keywords
This publication has 38 references indexed in Scilit:
- Whole body correction of mucopolysaccharidosis IIIA by intracerebrospinal fluid gene therapyJCI Insight, 2013
- Long-Term Expression and Safety of Administration of AAVrh.10hCLN2 to the Brain of Rats and Nonhuman Primates for the Treatment of Late Infantile Neuronal Ceroid LipofuscinosisHuman Gene Therapy Methods, 2012
- Mucopolysaccharidosis type IIIA: Clinical spectrum and genotype‐phenotype correlationsAnnals of Neurology, 2010
- Efficient intracerebral delivery of AAV5 vector encoding human ARSA in non-human primateHuman Molecular Genetics, 2009
- Intravenous Administration of Self-complementary AAV9 Enables Transgene Delivery to Adult Motor NeuronsMolecular Therapy, 2009
- Human α-Iduronidase Gene Transfer Mediated by Adeno-Associated Virus Types 1, 2, and 5 in the Brain of Nonhuman Primates: Vector Diffusion and BiodistributionHuman Gene Therapy, 2009
- Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytesNature Biotechnology, 2008
- Sanfilippo syndrome: A mini‐reviewJournal of Inherited Metabolic Disease, 2008
- Central nervous system therapy for lysosomal storage disordersNeurosurgical Focus, 2008
- Scoring Evaluation of the Natural Course of Mucopolysaccharidosis Type IIIA (Sanfilippo Syndrome Type A)PEDIATRICS, 2007